Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline þ fluticasone propionate in patients with COPD
Articolo
Data di Pubblicazione:
2004
Citazione:
Salmeterol/fluticasone propionate in a Single Inhaler Device versus
theophylline þ fluticasone propionate in patients with COPD / M. Cazzola, P. Noschese, S. Centanni, P. Santus, F. Di Marco, L. Spicuzza, G.U. Di Maria. - In: PULMONARY PHARMACOLOGY & THERAPEUTICS. - ISSN 1094-5539. - 17:3(2004), pp. 141-145. [10.1016/j.pupt.2004.01.004]
Abstract:
Study objectives. The aim of this study was to compare the relative efficacy in terms of improvement in symptoms and lung function of
salmeterol/fluticasone propionate (SLM/FP) combination administered through the Diskus inhaler versus theophylline (THEO) added to FP
Diskus in patients with stable chronic obstructive pulmonary disease (COPD).
Methods and measurements. Eighty patients were randomized to receive 4 months of treatment in one of two treatment groups: (1) fixed
combination of SLM 50 mg and FP 500 mg Diskus, 1 inhalation twice daily; or (2) FP Diskus 500 mg, 1 inhalation twice daily, plus oral
titrated THEO twice daily. Patients attended the clinic before and after 4, 8, 12 and 16 weeks of treatment for evaluations of pulmonary
function, and dyspnea, which was assessed using an analogic visual scale. Also the supplemental salbutamol use was measured.
Results. Sixty-six patients completed the 4-month treatment period: 37 patients receiving SLM/FP and 29 patients receiving THEO þ FP.
Patients were withdrawn for various reasons, the most common of which were poor compliance with the protocol, exacerbation and GI
events. A gradual increase in FEV1 was observed with each treatment. Maximum significant increases in FEV1 over baseline values that were
observed after 4 months of treatment were as follows: SLM/FP 0.172 l (95% CI: 0.084–0.260) and THEO þ FP 0.155 l (95% CI: 0.054–
0.256). SLM/FP experienced significantly ðp , 0:05Þ greater improvements in dyspnea, and required significantly fewer supplemental
salbutamol treatments than the THEO þ FP group.
Conclusions. Our results suggest that SLM/FP combination may provide substantial benefits in both physiologic and clinical outcomes in
symptomatic patients with COPD. It also causes a more effective control than THEO þ FP
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Chronic obstructive pulmonary disease; Combination therapy; Fluticasone propionate; Salmeterol; Theophylline
Elenco autori:
M. Cazzola, P. Noschese, S. Centanni, P. Santus, F. Di Marco, L. Spicuzza, G.U. Di Maria
Link alla scheda completa: